ADA at a glance
Identify the most relevant presentations and cross-cutting trends shaping clinical practice, translational science, and AI-enabled diabetes care.
📅 Build your schedule around the topics that interest you. 📥 Download the ADA_2025_Preview_by_LucidQuest
Dive deeper
Key Topics From ADA 2025 Scientific Presentations
Cardio-Renal 🔍
- Triglyceride variability raises HF risk (ACCORD HR 1.24).
- SGLT2i/GLP-1RA cut DKD events only when baseline ACR ≥ 30 mg/g.
- KidneyIntelX doubles risk-stratification accuracy in CANVAS/CREDENCE.
Clinical Trials 💉
- Dual incretins (HDM1005, HRS9531): >10% weight loss & −2.7% HbA1c.
- IL-22 agonist (CK-0045) and adiponectin agonist (PEG-BHD1028) hit insulin-resistance/lipid targets without major AEs.
- Baricitinib tempers NK activity in new-onset T1D.
Diabetes Care 🩺
- SWEET global data: tech gaps drive higher HbA1c in low-GDP nations.
- iLet bionic pancreas, MiniMed 780G, and iGlarLixi lower HbA1c with minimal hypoglycemia.
- Cofrogliptin and HRS-7535 add oral options in real-world use.
Behavioral & Lifestyle 🧠
- HAPPY-T1D tele-program lifts Time-in-Range.
- Culturally tailored DSMES boosts engagement in Black adults.
- Sleep-extension mHealth trends toward better glycemia.
Health Equity 🌍
- Eliminating Barriers model trims HbA1c by ~2% via SDoH support.
- T1D Exchange: workforce mismatch flags need for provider diversity.
- CME-driven screening ups hypercortisolism detection.
Obesity ⚖️
- Next-gen GLP-1/GIP agonists (BGM0504, Amycretin) slice bodyweight up to 24%.
- Oral biased GLP-1RAs show meaningful loss with mild GI effects.
- Rapid-loss alopecia flagged as AOM safety note.
Artificial Intelligence and Machine Learning at ADA 2025
Predictive Glycemia 🤖
- XGBoost hits 89% accuracy forecasting drug response; wearable HR + steps marginally sharpen glucose prediction during exercise.
Risk Stratification 📊
- Saudi cohort AI beats standard ASCVD scores (AUROC 0.80).
- RF predicts HF death at 85% accuracy; ML flags severe stenosis with 94.7% sensitivity.
CGM Analytics 📈
- SmartGuide alerts curb hypo/hyper extremes; CGM metrics outclass HbA1c for severe hypo risk.
Retinal AI 👁️
- Fundus-based model estimates HbA1c (R² 0.84); EyeArt screening lifts follow-up to 51%.
Pharmacogenomics 🧬
- AlphaFold shows GLP-1R A316T lowers tirzepatide binding, supporting genotype-guided incretin therapy.
Equity AI 🌐
- ML pinpoints tech-use barriers in underserved teens; GraphSAGE reweights All of Us data for national representativeness (SMD 0.123 → 0.077).
📅 Build your schedule around the topics that interest you.
📥 Download the ADA_2025_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.